ARS Pharmaceuticals, Inc.

SPRY · Biotech · Nasdaq · As of 10 Sep 2026

FundamentalsNot enough data yet
ValueWeak
News flowBalanced
MomentumWeak
SafetyBalanced

Overall confidence 57/100 — a solid read; one perspective is still filling in

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Medium (15/100) · Gap confidence 56/100Some evidence isn't yet fully priced in.

This month at a glance

AIR Score™ change: 0AIR Score™ held steady this month.

Cycle window9 Sep 2026 → 10 Sep 2026

MoversNothing moved meaningfully this month.

Evidence timeline

[8-K 2.02] ARS Pharmaceuticals, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 13, 2026 · 8-K
[8-K 5.02] ARS Pharmaceuticals, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Jul 15, 2026 · 8-K
[8-K 5.02] ARS Pharmaceuticals, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Jul 6, 2026 · 8-K
[8-K 2.02] ARS Pharmaceuticals, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 15, 2026 · 8-K
[8-K 5.02] ARS Pharmaceuticals, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
May 12, 2026 · 8-K
[8-K 2.02] ARS Pharmaceuticals, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Mar 9, 2026 · 8-K
[8-K 2.02] ARS Pharmaceuticals, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Nov 10, 2025 · 8-K
[8-K 1.01] ARS Pharmaceuticals, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Sep 29, 2025 · 8-K
[8-K 2.03] ARS Pharmaceuticals, Inc. — Creation of a Material Direct Financial ObligationSEC · SEC EDGAR
Sep 29, 2025 · 8-K
[8-K 8.01] ARS Pharmaceuticals, Inc. — Other EventsSEC · SEC EDGAR
Aug 13, 2025 · 8-K
[8-K 2.02] ARS Pharmaceuticals, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 13, 2025 · 8-K
[8-K 2.02] ARS Pharmaceuticals, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 14, 2025 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.